Patients who have cirrhosis have a greater frequency of complications related to medications than do those without cirrhosis 25% vs. 8% 2, 4, 11-13. They must be thoroughly monitored during treatment, and those with cytopenia must be evaluated for the activity of thiopurine methyltransferase before administration of azathioprine 2, 4, 11-13, 11, 65, 66, 68, 75.
Estos pacientes tienen una mayor frecuencia de complicaciones relacionadas con los medicamentos que aquellos sin cirrosis 25% versus 8% 2, 4, 11-13; deben ser monitorizados estrechamente durante el tratamiento y a las personas con citopenias se les deben evaluar la actividad de tiopurina metiltransferasa antes de la administración de azatioprina 2, 4, 11-13, 11, 65, 66, 68, 75.